SGMT NASDAQ
Credit Risk of going bust: lower than 64% of companies Debt: 0.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down 99.9%), Sagimet Biosciences Inc. would be worth roughly what it owes.
Total debt $1.9M against a stock market value of $311.5M.
Distance to default 6.72 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $970K (short-term plus half of long-term), stock volatility 81.8%; Altman Z'' 37.05. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
San Mateo, CA 94402
US
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The companyâs lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kemble George | M-Exempt | 326,618 | $6.36 | 2026-08-14 |
| Kemble George | M-Exempt | 24,369 | $6.36 | 2026-08-14 |
| Kemble George | S-Sale | 350,987 | $10.23 | 2026-08-14 |
| Kemble George | M-Exempt | 326,618 | $6.36 | 2026-08-14 |
| Kemble George | M-Exempt | 24,369 | $6.36 | 2026-08-14 |